Considerations Following Locoregional Therapy in HCC
Videos
Initial Strategies in Advanced HCC
Initial Strategies in Advanced HCC
Management of Platinum-Resistant Ovarian Cancer
Hope S. Rugo, MD, discusses the differentiating factors of abemaciclib among the CDK 4/6 inhibitors for breast cancer treatment.
Anees B. Chagpar, MD, associate professor of Surgery (Oncology), director of The Breast Center at Smilow Cancer Hospital at Yale-New Haven, Yale Cancer Center, discusses ongoing clinical trials in the field of triple-negative breast cancer (TNBC).
Treatment of EGFR Mutant Non-Small Cell Lung Cancer
Charles M. Rudin, MD, PhD, chief, thoracic oncology, Memorial Sloan Kettering Cancer, discusses a study of intravenously delivered coxsackievirus A21 with pembrolizumab to treat patients with advanced cancers.
Dhanya K. Nambiar, PhD, Stanford University, discusses a study exploring galectin-1 in combination with radiation and immune checkpoint therapy in head and neck cancers.
Rekha Rao, PhD, assistant professor, University of Kansas Medical Center, discusses a study of the synergistic activity of p97 inhibitors with histone deacetylase 6 inhibitors in mantle cell lymphoma (MCL).